

Discovery of AR-targeting ATTEC compounds for treating prostate cancer

Korea Research Institute of Chemical Technology / Therapeutics & Biotechnology Division



ONCOLOGY	Lead
Product Type	Small molecule (ATTEC, TPD compound)
Indication	Prostate cancer
Target	Androgen receptor
MoA(Mechanism of Action)	AR-ATTEC tethers AR protein to autophagosome through its interaction with LC3, it is directed for autophagic degradation of target protein.
Competitiveness	Compounds that can treat resistant prostate cancer to existing therapies using autophagy system.
Development Stage	Lead
Route of Administration	Oral